<DOC>
	<DOCNO>NCT00878254</DOCNO>
	<brief_summary>The investigator ( ) hypothesize Rituximab together combination chemotherapy , follow Rituximab maintenance therapy , provide good disease control improve response rate overall survival patient previously untreated Mantle Cell Lymphoma ( MCL ) .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Previously Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description>This phase 2 study Rituximab combination Methotrexate , Doxorubicin , Cyclophosphamide , Leucovorin , Vincristine , Ifosfamide , Etoposide , Cytarabine Mesna ( R-MACLO/IVAM ) subject previously untreated Mantle Cell Lymphoma ( MCL ) . Treatment consist 4 cycle therapy . Response assessment CT PET scan perform post Cycle 2 . Once final cycle therapy complete , response evaluation perform base pre-study CT scan , PET/ Scan/endoscopy stag scan positive baseline . ( PI approval require treat less 4 cycle ) . Subjects complete remission give Rituximab per institution guideline , 4 weekly dos every 6 month total 3 year , progression disease , subject unable tolerate treatment . Rituximab begin 6 month date discharge +/- 21 day . Maintenance therapy , premedications change base clinical consideration treat physician . Timelines give premedications give per institutional guideline . Subject may discharge administration Rituximab , stable .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Previously untreated , histologically confirm mantle cell lymphoma , 2 . Measurable evaluable disease ( least one site &gt; 1.5 cm diameter 3 . All stage eligible 4 . Age &gt; 18 year 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 6 . Adequate hepatic function : Bilirubin &lt; 3 mg/dL Transaminases ( serum glutamic oxaloacetic transaminase ( SGOT ) and/or serum glutamatepyruvate transaminase ( SGPT ) ) &lt; 2.5 time upper limit normal institution , unless due lymphomatous involvement 7 . Serum creatinine &lt; 1.5 mg/dl 8 . Ability give inform consent 9 . Women childbearing potential must negative pregnancy test within 72 hour enter study . Males females must agree use adequate birth control conception possible study . Women must avoid pregnancy men avoid father child study . 10 . Life expectancy great 6 month . 1 . Previous chemotherapy , immunotherapy radiotherapy mantle cell lymphoma 2 . Concurrent active malignancy , exception situ carcinoma cervix basal cell carcinoma skin . 3 . Grade 3 4 cardiac failure and/or ejection fraction &lt; 50 . 4 . Psychological , familial , sociological geographical condition permit treatment and/or medical followup require comply study protocol . 5 . Patients known history human immunodeficiency virus ( HIV ) Acquired Immunodeficiency Syndrome ( AIDS ) . 6 . Presence hepatitis hepatitis B virus ( HBV ) infection . 7 . Pregnant breastfeed woman . 8 . Central Nervous System ( CNS ) involvement .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>MCL</keyword>
	<keyword>NHL</keyword>
</DOC>